Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Conatus Pharmaceutic (CNAT)

Conatus Pharmaceutic (CNAT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 18,443
  • Shares Outstanding, K 33,170
  • Annual Sales, $ 21,720 K
  • Annual Income, $ -11,390 K
  • 60-Month Beta 1.84
  • Price/Sales 0.85
  • Price/Cash Flow N/A
  • Price/Book 1.05
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.34
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/07/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3300 +68.48%
on 04/28/20
0.7500 -25.87%
on 05/21/20
+0.2139 (+62.53%)
since 04/24/20
3-Month
0.2303 +141.42%
on 03/16/20
0.7500 -25.87%
on 05/21/20
+0.1465 (+35.78%)
since 02/26/20
52-Week
0.2303 +141.42%
on 03/16/20
1.0700 -48.04%
on 06/19/19
-0.2790 (-33.41%)
since 05/24/19

Most Recent Stories

More News
Histogen Announces Successful Completion of its Merger with Conatus Pharmaceuticals

Histogen Inc. (NASDAQ: HSTO), a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today the completion of its previously disclosed...

HSTO : 4.24 (-8.03%)
CNAT : 0.5560 (+0.18%)
Acute Kidney Injury Treatment Market Present And Upcoming Trends With COVID 19 Impact Study | Novartis AG, Pfizer Inc, Ipsen SA

MarketResearch.Biz published a new industry research report “Acute Kidney Injury Treatment Market” in its database. This is a latest report, including the present COVID-19 impact and future effect on...

CNAT : 0.5560 (+0.18%)
IPSEY : 19.9200 (+5.29%)
MRK : 79.04 (+1.92%)
NVS : 86.28 (+2.17%)
PFE : 38.18 (+2.06%)
TEVA : 12.92 (+0.08%)
VRX.TO : 30.80 (-3.33%)
Leading Independent Proxy Advisory Firms Recommend Conatus Pharmaceuticals Shareholders Vote in Favor of its Merger with Histogen and the Required Reverse Stock Split

Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that Institutional Shareholder Services Inc. (ISS) and Glass Lewis, two leading independent research and proxy advisory firms that provide institutional...

CNAT : 0.5560 (+0.18%)
Histogen Publishes Preclinical Data on its HST 004 Spinal Disc Program

Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today the publication of data on HST 004, its patented, naturally-derived...

CNAT : 0.5560 (+0.18%)
Histogen Receives US FDA IND Approval to Initiate Phase 1b/2a Trial of HST 001 in Androgenic Alopecia

Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today that the U.S. Food and Drug Administration (FDA) has approved...

CNAT : 0.5560 (+0.18%)
The Conatus Pharmaceuticals Special Meeting of Stockholders Seeking Approval for Proposed Merger with Histogen Inc. will Reconvene on May 21, 2020

Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today convened and adjourned its special meeting of stockholders in order to obtain a quorum and specific stockholder approvals required pursuant to the terms...

CNAT : 0.5560 (+0.18%)
Conatus: 1Q Earnings Snapshot

SAN DIEGO (AP) _ Conatus Pharmaceuticals Inc. (CNAT) on Friday reported a loss of $3.5 million in its first quarter.

CNAT : 0.5560 (+0.18%)
Conatus Pharmaceuticals Reports First Quarter 2020 Financial Results and Strategic Process Update

Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the first quarter ended March 31, 2020 and provided an update on its strategic process.

CNAT : 0.5560 (+0.18%)
Histogen Announces Investigational Device Exemption Application for HST 002

Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today that it has submitted an Investigational Device Exemption...

CNAT : 0.5560 (+0.18%)
Histogen Publishes New Preclinical Data on its HST 003 Orthopedic Program

Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today the publication of data on its human extracellular matrix...

CNAT : 0.5560 (+0.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade CNAT with:

Business Summary

Conatus Pharmaceuticals, Inc. is a biotechnology company. It is focused on developing and commercializing medicines to treat liver disease. The Company is developing its lead compound, emricasan, for the treatment of patients in orphan populations with chronic liver disease and acute exacerbations of...

See More

Key Turning Points

2nd Resistance Point 0.6169
1st Resistance Point 0.5865
Last Price 0.5560
1st Support Level 0.5331
2nd Support Level 0.5101

See More

52-Week High 1.0700
Fibonacci 61.8% 0.7492
Fibonacci 50% 0.6502
Last Price 0.5560
Fibonacci 38.2% 0.5511
52-Week Low 0.2303

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar